Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
Search
Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
More
Search
Home
Tags
FDA
FDA
Press Releases
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
DMD
Explore Of 5 Phases In Drug Development
Press Releases
Solid Biosciences Plans to Request a Meeting with the FDA in mid-2025 to Discuss Potential Accelerated Approval Pathways for SGT-003
Press Releases
GenAssist Announces FDA Approval of New Drug Application for GEN6050X Exon 50 Skipping Therapy
Press Releases
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Editorials
Clinical Trials Review of Elevidys Gene Therapy: Is Elevidys Cost Worthy?
Approved Treatments
FDA-Approved Treatments for DMD (Duchenne Muscular Dystrophy)
Press Releases
FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04)
Press Releases
3 Drugs Receiving Accelerated Approval from the FDA and Reviewed by the Office of Inspector General Raised Concerns
1
2
Page 1 of 2
Popular
Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy
DMD Warrior
-
December 26, 2024
Must Read
Press Releases
Translarna (Ataluren) Rejected by EMA: Marketing Authorization Not Renewed
Editorials
DMD WarrioR’s Turkish Representative Shares His Views on Elevidys Gene Therapy: Is It Effective and Why Is It Expensive?
Research
Fn14 Protein May Protect Muscle Stem Cells, Offering Promise for Development of Duchenne Treatments
